An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors
13. August 2026 aktualisiert von: University of Michigan Rogel Cancer Center
Feasibility, Usability, and Acceptability of an AI-Powered MASCC Supportive Care Platform Among Young Adults With Cancer
This clinical trial studies whether an artificial intelligence (AI)-powered supportive care chatbot is helpful for addressing the supportive care needs of young adult cancer survivors.
Young adult cancer survivors often experience ongoing and distressing symptoms following treatment, including extreme tiredness and lack of energy, anxiety, and difficulty sleeping.
Young adult cancer survivors report a variety of strategies to self-manage these symptoms; however, there remains a gap in targeted interventions focused on the needs in young adult survivors.
The AI-powered supportive care chatbot is designed to provide evidence-based information on supportive care for young adult cancer survivors.
Users interact with the chatbot by entering free-text questions or selecting from predefined topics to receive tailored educational responses related to supportive care across the cancer continuum, including treatment effects, symptom management, care transitions, and life after cancer.
The AI-powered supportive care chatbot may be an effective way to help address the supportive care needs of young adult cancer survivors.
Studienübersicht
Status
Noch keine Rekrutierung
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Geschätzt)
30
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Robert Knoerl
- Telefonnummer: 734-764-8617
- E-Mail: rjknoerl@med.umich.edu
Studienorte
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Rogel Cancer Center
-
Kontakt:
- Robert Knoerl
- Telefonnummer: 734-764-8617
- E-Mail: rjknoerl@med.umich.edu
-
Hauptermittler:
- Robert Knoerl
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- 18 - 39 years old
- Able to speak/read English
- Completed primary cancer treatment (e.g., surgery, radiation, chemotherapy, immunotherapy) at least one month prior to the time of consent. Although, participants will be eligible if they are receiving maintenance treatments
- Report at least one moderate to severe symptom, side effect, or supportive care concern from cancer or its treatment
- Able to access Wi-Fi/internet
- Willing to complete surveys electronically
Exclusion Criteria:
- Completed cancer treatment more than three years ago
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Supportive care (AI-powered supportive care chatbot)
Patients interact with AI-powered supportive care chatbot in a self-directed manner for 4 weeks.
Following the initial 4-week use period, patients choose to either continue to use the chatbot for an additional 8 weeks or conclude study participation.
|
Nebenstudien
Nebenstudien
Interact with AI-powered supportive care chatbot
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Acceptability of AI-powered supportive care chatbot
Zeitfenster: At end of intervention, assessed up to 12 weeks
|
Acceptability will be supported if mean scores on the Acceptability E-Scale are ≥ 4 (on a 5-point scale).
Will be described (i.e., means, medians, standard deviations, and ranges) at the post-intervention time point.
|
At end of intervention, assessed up to 12 weeks
|
|
Demand of AI-powered supportive care chatbot
Zeitfenster: Up to 12 months
|
Demand will be demonstrated by successful recruitment of the target sample (N=30) within 12 months.
|
Up to 12 months
|
|
Implementation of AI-powered supportive care chatbot
Zeitfenster: During intervention use, assessed up to 12 weeks
|
Implementation will be assessed by engagement with the chatbot, defined as ≥ 70% of participants reporting at least one use per week during the initial 4-week period, rather than a fixed duration of use, given the self-directed nature of the intervention.
Will be described (i.e., means, medians, standard deviations, and ranges) weekly.
Given the pilot nature of the study, no hypothesis testing or formal comparisons will be conducted.
|
During intervention use, assessed up to 12 weeks
|
|
Retention
Zeitfenster: Up to 12 weeks
|
Retention will be considered feasible if ≥ 80% of participants complete 4-week assessments, and ≥ 50% elect to continue to the optional extended use period.
|
Up to 12 weeks
|
|
Usability of AI-powered supportive care chatbot
Zeitfenster: At end of intervention, assessed up to 12 weeks
|
Usability will be supported if mean System Usability Scale scores are ≥ 70, indicating acceptable usability.
Will be described (i.e., means, medians, standard deviations, and ranges) at the post-intervention time point.
|
At end of intervention, assessed up to 12 weeks
|
|
Patient Reported Outcomes Measurement Information System measure
Zeitfenster: At baseline, 4 weeks, and/or 12 weeks
|
Will be summarized using descriptive statistics (e.g., means, medians, standard deviations, and ranges) at each time point.
Changes over time (baseline, post-intervention, as applicable) will be examined descriptively.
|
At baseline, 4 weeks, and/or 12 weeks
|
|
Digital Health Literacy Scale
Zeitfenster: At baseline
|
Will be summarized using descriptive statistics (e.g., means, medians, standard deviations, and ranges) at the baseline time point.
The Digital Health Literacy Scale is a 0 to 12 point score (based on 3 items), with higher scores indicating greater digital health care literacy.
|
At baseline
|
|
Interview themes and subthemes
Zeitfenster: At end of intervention, assessed up to 12 weeks
|
The audio-recorded interviews will be transcribed verbatim by a professional transcription company and verified for accuracy by another study team member.
The finalized transcripts will be imported into NVivo 12 (QSR International Pty Ltd).
Inductive content analysis will be used to analyze the interview transcripts.
Two study team members will review the transcripts and the interview guide to create an initial list of codes.
Three transcripts will be independently coded using the initial codebook.
After three interviews are coded, two study team members will meet to resolve any coding discrepancies and to revise the codebook further.
The same process will be repeated after three more interviews are coded.
After the codebook is finalized, one study team member will code the remaining interviews.
Subsequently, the study team will meet as a group to review the transcripts in their entirety, making sense of the data and generating potential major themes and subthemes.
|
At end of intervention, assessed up to 12 weeks
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Robert Knoerl, University of Michigan Rogel Cancer Center
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Oktober 2026
Primärer Abschluss (Geschätzt)
1. Oktober 2028
Studienabschluss (Geschätzt)
1. Oktober 2028
Studienanmeldedaten
Zuerst eingereicht
30. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
13. August 2026
Zuerst gepostet (Tatsächlich)
19. August 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
19. August 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
13. August 2026
Zuletzt verifiziert
1. Juli 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- UMCC 2026.025
- NCI-2026-05454 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- HUM00288074 (Andere Kennung: University of Michigan Rogel Cancer Center)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Beschreibung des IPD-Plans
De-identified participant data will be shared with other researchers upon reasonable request and execution of a data transfer agreement.
IPD-Sharing-Zeitrahmen
After publication of results and within 7 years after study completion.
IPD-Sharing-Zugriffskriterien
De-identified participant data will be shared with other researchers upon reasonable request and execution of a data transfer agreement.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .